glucocorticoids
Synthetic corticosteroids differ primarily in glucocorticoid potency, mineralocorticoid activity, and biological half-life. Use hydrocortisone for physiological adrenal insufficiency replacement and adrenal crisis (provides mineralocorticoid cover at stress doses), prednisone/methylprednisolone for anti-inflammatory/immunosuppressive therapy, dexamethasone when maximal anti-oedema/anti-inflammatory potency without sodium retention is needed (or diagnostic testing), and fludrocortisone solely for mineralocorticoid replacement in primary adrenal insufficiency.
Courses ≥3–4 weeks at supraphysiologic doses can suppress the HPA axis for months — never stop abruptly without assessing recovery or tapering, and treat intercurrent severe illness/surgery with stress-dose hydrocortisone. Conversely, courses <3–4 weeks (any dose) can be stopped without tapering (ESE/ES 2024).
mechanism
Bind intracellular glucocorticoid receptors (transrepression of NF-κB/AP-1 inflammatory cytokines; transactivation of metabolic genes) and, to varying degrees, mineralocorticoid receptors (renal Na⁺ retention and K⁺/H⁺ excretion).
comparison and equivalent dosing
Approximate systemic conversion guide (ESE/ES 2024 Table 1; individual metabolism and route vary):
| agent | approx. equivalent dose | relative GC potency | mineralocorticoid activity | biologic half-life | primary clinical role |
|---|---|---|---|---|---|
| hydrocortisone | 20 mg | 1.0 | moderate (1.0) | 8–12 h | AI replacement (15–25 mg/d divided), adrenal crisis (100 mg IV → 200 mg/24 h), labour/peri-op stress |
| cortisone acetate | 25 mg | 0.8 | moderate (0.8) | 8–12 h | AI replacement (prodrug; requires hepatic 11β-HSD1 activation — avoid in severe liver failure) |
| prednisone | 5 mg | 4.0 | mild (0.8) | 12–36 h | oral anti-inflammatory/immunosuppressant; alternative AI replacement (3–5 mg/d); prodrug → prednisolone |
| prednisolone | 5 mg | 4.0 | mild (0.8) | 12–36 h | active form of prednisone; preferred over prednisone in severe hepatic failure |
| methylprednisolone | 4 mg | 5.0 | minimal (0.5) | 12–36 h | IV anti-inflammatory/pulse therapy (e.g., 500–1000 mg IV daily × 3 d in severe vasculitis/MS/thyroid eye disease) |
| dexamethasone | 0.5–0.75 mg | 30–60 | none (0) | 36–72 h | CNS tumour oedema, bacterial meningitis, severe COVID-19, antiemesis, 1-mg DST (does not cross-react on cortisol assay); highest HPA suppression |
| fludrocortisone | — | 10 (at usual 0.05–0.1 mg dose, negligible GC effect) | very high (~125) | 18–36 h | mineralocorticoid replacement in primary AI only (50–100 µg PO daily) and neurogenic orthostatic hypotension |
- Physiologic daily dose equivalent: hydrocortisone 15–25 mg/day ≈ prednisone 4–6 mg/day (ESE/ES 2024)
- Stress-dose hydrocortisone (>50 mg/day) has sufficient mineralocorticoid potency that fludrocortisone is held during adrenal crisis or major surgical stress
key points
- Tapering and HPA recovery (ESE/ES 2024):
- <3–4 weeks of systemic therapy: stop without tapering
- ≥3–4 weeks: switch long-acting agents (dexamethasone/betamethasone) to hydrocortisone or prednisone once acute indication resolves; taper to physiologic equivalent (prednisone 4–6 mg/day) once underlying disease is controlled
- Check morning serum cortisol (hold morning dose 24 h): >300 nmol/L → stop safely; 150–300 nmol/L → continue physiologic dose and repeat in weeks–months; <150 nmol/L → continue and repeat in months (avoid routine cosyntropin testing)
- Never give fludrocortisone for glucocorticoid-induced AI
- Pregnancy: hydrocortisone, prednisone, and prednisolone are inactivated by placental 11β-HSD2 (safe for maternal indications); dexamethasone and betamethasone cross the placenta (avoid for maternal AI; used intentionally only for foetal lung maturity)
- Bone protection (ACR GIOP 2022): anyone starting ≥2.5 mg/day prednisone equivalent for ≥3 months needs fracture risk assessment, calcium/vitamin D optimisation, and bone-directed therapy per risk tier (see osteoporosis and osteoporosis agents)
- Diagnostic interference: dexamethasone does not cross-react in serum cortisol immunoassays (useful if steroid is urgently needed before a cortisol blood draw, though it suppresses endogenous ACTH rapidly); hydrocortisone and prednisolone cross-react heavily
- Key drug interactions:
- CYP3A4 inducers (rifampin, phenytoin, carbamazepine) → accelerate glucocorticoid clearance → may precipitate adrenal crisis in AI (increase replacement dose) and cause false-positive 1-mg DST
- CYP3A4 inhibitors (ritonavir, cobicistat, itraconazole) → inhibit clearance of inhaled/intranasal fluticasone or intra-articular triamcinolone → iatrogenic cushing syndrome and profound HPA suppression
- NSAIDs / anticoagulants → additive GI bleeding risk → consider PPI prophylaxis when combined with systemic steroids
adverse effects
- Endocrine/metabolic: HPA-axis suppression and adrenal crisis on abrupt withdrawal, iatrogenic cushing syndrome, hyperglycaemia / steroid-induced diabetes (characteristically afternoon/post-prandial peak with morning prednisone), dyslipidaemia, fluid retention and hypertension (least with dexamethasone)
- Musculoskeletal: osteoporosis and rapid vertebral fracture risk (highest in first 3–6 months), avascular necrosis (femoral head), proximal steroid myopathy
- Infectious: reactivation of latent TB, HBV, Strongyloides (screen before prolonged high-dose therapy in at-risk patients), PJP (prophylaxis typically considered at ≥20 mg/day prednisone for ≥4 weeks with additional risk factors), oral candidiasis
- Neuropsychiatric & ocular: insomnia, mood lability, steroid-induced psychosis, posterior subcapsular cataracts, elevated intraocular pressure/glaucoma
- GI & dermatologic: peptic ulcer/GI bleed (especially with NSAIDs), skin thinning, easy bruising, impaired wound healing
Prepared 2026-11-19. Not yet verified — check every number against the sources.